Key Takeaways
- DataMeds AI partnered with Tollo Health to introduce the Health Lives Here mobile platform for individuals using GLP-1 medications.
- The platform is being distributed via a collaboration with NFL Alumni Health.
- An initial pharmacy network launched with Moose Pharmacy of Concord in North Carolina as its first member.
- MEDS shares dropped 11% following the announcement.
- Future expansions target Long COVID and cancer patient groups in 2026 and beyond.
DataMeds AI (MEDS) shares tumbled 11% Monday following the company’s unveiling of a new healthcare application. The stock settled at $3.11 during trading.
The Florida-based firm collaborated with Tollo Health to introduce Health Lives Here, a mobile platform designed primarily for individuals taking GLP-1 receptor agonist drugs.
The application is being promoted via a strategic alliance with NFL Alumni Health, the wellness division of the National Football League Alumni Association.
Initial Pharmacy Partner Network Launches
Accompanying the app debut is the Health Lives Here healthcare network. The network begins with select independent pharmacies drawn from the existing roster of Corexa Health, a DataMeds subsidiary.
North Carolina’s Moose Pharmacy of Concord serves as the inaugural network participant. Additional pharmacy locations are anticipated to come aboard gradually.
Users of the platform can access licensed physicians for remote medical consultations. The telemedicine feature enables patients to receive evaluations for GLP-1 treatment options directly through their smartphones.
Through Corexa’s pharmaceutical division, patients can purchase brand-name GLP-1 medications on a cash-pay basis. The service includes home delivery, though users also maintain the option to transfer prescriptions to their preferred local pharmacy.
Additionally, the platform offers Forzet from Tollo Health, a medical food formulation. This product aims to address muscle mass reduction often associated with weight loss therapies and is available without prescription requirements.
Advanced Technology Integration and AI Capabilities
Health Lives Here syncs with leading wearable technology devices, including Apple Watch, Samsung Galaxy Watch, WHOOP bands, and Oura Ring.
The platform features an artificial intelligence-powered health coaching system along with comprehensive activity tracking functionality. An integrated AI chatbot monitors communications for crisis indicators and can direct users to emergency resources when needed.
DataMeds AI has outlined ambitions extending beyond GLP-1 medication users. The firm intends to broaden the platform’s reach to Long COVID patients during the final quarter of 2026.
Subsequent expansion will target cancer patient populations, though specific timing for this phase remains unannounced.
Diagnostic laboratory services are also under development. These capabilities would leverage the company’s purchase of Helomics Corporation, enabling consumers to request lab testing directly in jurisdictions where regulations permit.
Long-term objectives include incorporating digital twin technology. An expanded provider network is scheduled for 2027.
Gerald Commissiong holds the position of Interim Co-CEO at DataMeds AI while simultaneously serving as CEO of Tollo Health, the collaborative partner behind the app launch.
The substantial stock decline contrasts sharply with the product announcement. Market participants may be assessing implementation challenges against the nascent stage of deployment.
Currently, the Health Lives Here application is operational with a single pharmacy partnership established. While the company has outlined an extensive multi-year development plan, it has not disclosed adoption metrics or revenue projections associated with the launch.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
